Verona Pharma plc (ADR)
General ticker "VRNA" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $5.4B (TTM average)
Verona Pharma plc (ADR) follows the US Stock Market performance with the rate: 46.4%.
Estimated limits based on current volatility of 0.0%: low 106.80$, high 106.90$
Factors to consider:
- Total employees count: 209 (+164.6%) as of 2024
- Earnings for 18 months up through Q2 (+1 year) are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [7.62$, 17.64$]
- 2024-12-30 to 2025-12-30 estimated range: [5.10$, 12.32$]
Financial Metrics affecting the VRNA estimates:
- Negative: with PPE of -26.8 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -3.60 <= 0.85
- Positive: Shareholder equity ratio, % of 80.90 > 62.86
- Negative: Industry operating cash flow per share per price (median), % of -13.21 <= 2.35
- Positive: Inventory ratio change, % of -84.51 <= -0.84
- Positive: Interest expense per share per price, % of 0.15 <= 0.71
- Negative: negative Net income
Short-term VRNA quotes
Long-term VRNA plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $40.00MM | $0.46MM | $0.00MM |
| Operating Expenses | $113.31MM | $76.21MM | $67.57MM |
| Operating Income | $-73.31MM | $-75.75MM | $-67.57MM |
| Non-Operating Income | $17.73MM | $7.30MM | $13.67MM |
| Interest Expense | $0.34MM | $0.52MM | $2.06MM |
| R&D Expense | $79.41MM | $49.28MM | $17.22MM |
| Income(Loss) | $-55.59MM | $-68.45MM | $-53.90MM |
| Taxes | $-0.02MM | $0.25MM | $0.47MM |
| Profit(Loss)* | $-55.57MM | $-68.70MM | $-54.37MM |
| Stockholders Equity | $148.00MM | $230.47MM | $249.28MM |
| Inventory | $4.04MM | $2.50MM | $0.00MM |
| Assets | $186.59MM | $259.47MM | $308.12MM |
| Operating Cash Flow | $-33.25MM | $-59.86MM | $-50.22MM |
| Capital expenditure | $0.01MM | $0.03MM | $0.00MM |
| Investing Cash Flow | $-0.01MM | $-0.03MM | $0.00MM |
| Financing Cash Flow | $-6.12MM | $140.82MM | $92.87MM |
| Earnings Per Share** | $-0.94 | $-1.04 | $-0.72 |
| Ordinary share to ADR | 0.12x | 0.12x | 0.12x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.